Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutic platform company, announced today that Zain Kassam, MD, MPH, has been appointed Chief Medical Officer (CMO) effective September 1, 2019. Dr. Kassam will lead the advancement of Finch’s microbiome therapeutics for recurrent C. difficile infection, ulcerative colitis, and autism spectrum disorder through the clinical development and regulatory submission process.
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, announced today the completion of a $53 million Series C financing. The financing comes from new investors including OCV Partners, Susquehanna International Group (SIG), Symbiosis LLC and the Trans-Pacific Technology Fund, as well as existing investors, including Avenir Growth Capital, Morgan Noble, Shumway Capital, and Willett Advisors.
On June 13, FDA reported that an immunocompromised patient treated with FMT died from a drug resistant infection. Importantly, this patient was not treated by Finch or our collaborator, OpenBiome. The FDA has communicated new mandatory screening standards, which Finch already exceeds. As a result, there is no impact on Finch’s work and our PRISM 3 and PRISM-EXT studies continue uninterrupted.
The infection occurred in a high-risk patient that received material from a donor that was not screened for a common drug resistant pathogen, resulting in exposure and subsequent infection. Finch has a thorough screening program which incorporates a panel of 30+ laboratory tests, including the agent associated with this adverse event, as part of our commitment to patient safety.
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its Full-Spectrum Microbiota® (FSM®) therapy for the treatment of children with Autism Spectrum Disorder (ASD). Fast Track designation is intended to facilitate development and expedite review of therapies designed to treat serious conditions and fill an unmet medical need.
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to investigational drug CP101 for the treatment of patients with recurrent Clostridium difficile (C. difficile) infection.
Finch Therapeutics Group, Inc. (Finch), a clinical-stage microbiome therapeutics company, announced today that the U.S. Patent and Trademark Office (USPTO) has issued six new patents to Finch covering its Full-Spectrum Microbiota (FSM) and Rationally-Selected Microbiota (RSM) product platforms.
Finch Therapeutics Group, Inc. (Finch), a clinical-stage microbiome therapeutics company, announced today that it has appointed Ulrich Thienel, Ph.D., M.D., as Chief Medical Officer and Gregory Perry as Chief Financial Officer.
Finch Therapeutics Group, Inc. (Finch), a privately held microbiome therapeutics company, announced today the successful close of an oversubscribed $36 million Series B financing, bringing the total capital raised since the Company’s launch to $77 million.
The new entity, Finch Therapeutics Group, combines Crestovo’s extensive IP assets and late-stage candidate for recurrent C. difficile infections, CP101, an oral Full-Spectrum Microbiota product, with Finch’s commercial-scale manufacturing capabilities, discovery platform for developing Rationally-Selected Microbiota therapies and significant product pipeline.
Under the terms of the agreement, Takeda will make an upfront payment of $10 million to Finch for the exclusive worldwide rights to develop and commercialize FIN-524 and rights to follow-on products in IBD. Finch will be eligible for development, regulatory and commercial financial milestones and tiered royalties on worldwide net sales.
Finch Therapeutics, Inc., a microbiome therapeutics company, and OpenBiome, a leading public stool bank, today announced a collaboration to develop FIN-403, an orally administered microbial therapy for approval by U.S. Food and Drug Administration (FDA) in recurrent C. difficile infections.
he Phloral technology will enable the first-in-human discovery approach at Finch. "Phloral is an exciting technology for our research into the microbiome because it enables oral delivery of communities with the same precise targeting as traditional but less convenient colonoscopic delivery,” says Dean Glettig, Director of Product Development at Finch.
"Finch Therapeutics is designing products comprised of pure cultures of microbes that will serve the same purposes of fecal microbiotas transplantation while also being safer and more scalable." -- Forbes